The newer, atypical antipsychotics were no better than a first-generation agent in reducing violent behavior in schizophrenic patients, researchers here said.
Among 1,445 patients randomly assigned to one of five antipsychotic drugs, the overall proportion showing violent behavior declined from 19% at baseline to 14% after six months on an intent-to-treat basis, with no differences seen between different medications, reported Marvin Swartz, M.D., of Duke University, and colleagues in the July 1 issue of the British Journal of Psychiatry.
They conducted a new analysis of data from the initial randomization phase of the prospective, double-blind Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project, a multi-center trial comparing the effectiveness of different drugs for schizophrenia.
"Contrary to high expectations and some previous research, this study did not show an advantage for second-generation antipsychotics in violence risk reduction when compared with perphenazine, a representative first-generation antipsychotic," the researchers wrote.
READ MORE @ MEDPAGE TODAY
Showing posts with label first generation antipsychotics(FGA). Show all posts
Showing posts with label first generation antipsychotics(FGA). Show all posts
Wednesday, July 2, 2008
Wednesday, June 18, 2008
FDA Orders Warning Label on Older Antipsychotics
The U.S. Food and Drug Administration is cautioning physicians that certain types of antipsychotic drugs can boost the death risk of seniors with dementia.
Doctors sometimes use antipsychotics to help treat behavioral problems in demented patients.
But from now on these older, so-called "conventional" antipsychotics -- which include drugs such as thorazine and prolixin -- will carry a new black box warning alerting physicians of the danger, FDA officials announced Monday.
"We issued letters to all the manufacturers of antipsychotic drugs, both conventional and atypical, requiring them to update their labeling with new language for a box warning about an increased risk of death in elderly patients with dementia," Dr. Thomas Laughren, director of the FDA's Division of Psychiatry Products at the Center for Drug Evaluation and Research, said during an afternoon teleconference.
This is a new warning for conventional antipsychotics, but it is not new for another class of the medications, called atypical antipsychotics. Back in 2005, the FDA ordered warning labeling for those medications, which include newer drugs such as Zyprexa and Risperdal. That labeling warned of a higher risk for heart attack and pneumonia for elderly patients with dementia who received atypical antipsychotics.
READ MORE @ WASHINGTON POST
Doctors sometimes use antipsychotics to help treat behavioral problems in demented patients.
But from now on these older, so-called "conventional" antipsychotics -- which include drugs such as thorazine and prolixin -- will carry a new black box warning alerting physicians of the danger, FDA officials announced Monday.
"We issued letters to all the manufacturers of antipsychotic drugs, both conventional and atypical, requiring them to update their labeling with new language for a box warning about an increased risk of death in elderly patients with dementia," Dr. Thomas Laughren, director of the FDA's Division of Psychiatry Products at the Center for Drug Evaluation and Research, said during an afternoon teleconference.
This is a new warning for conventional antipsychotics, but it is not new for another class of the medications, called atypical antipsychotics. Back in 2005, the FDA ordered warning labeling for those medications, which include newer drugs such as Zyprexa and Risperdal. That labeling warned of a higher risk for heart attack and pneumonia for elderly patients with dementia who received atypical antipsychotics.
READ MORE @ WASHINGTON POST
Subscribe to:
Posts (Atom)
